#1 Clinical Trials Search in Europe

Nemolizumab

Nemolizumab is an investigational drug being studied in clinical trials for its potential to treat various skin conditions, primarily moderate-to-severe atopic dermatitis. This article summarizes key findings from recent clinical trials evaluating the efficacy and safety of nemolizumab for atopic dermatitis and other dermatological disorders.

Table of Contents

What is Nemolizumab?

Nemolizumab, also known by its research code CD14152, is a medication being studied for the treatment of various skin conditions[1]. It is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein designed to target specific substances in the body. Nemolizumab is not yet approved for general use and is still undergoing clinical trials to determine its effectiveness and safety.

What Conditions Does Nemolizumab Treat?

Nemolizumab is being investigated for several skin conditions, including:

  • Moderate-to-severe atopic dermatitis: A chronic, itchy skin condition also known as eczema[2]
  • Prurigo nodularis: A skin disease characterized by intensely itchy nodules or lumps on the skin[3]
  • Chronic kidney disease-associated pruritus: Severe itching that occurs in people with chronic kidney disease[4]
  • Systemic sclerosis: A rare autoimmune disease that causes hardening and tightening of the skin and connective tissues[5]

How Does Nemolizumab Work?

Nemolizumab works by targeting a specific protein in the body called interleukin-31 (IL-31). This protein is involved in causing itching and inflammation in various skin conditions. By blocking IL-31, nemolizumab aims to reduce itching and improve the overall condition of the skin[2][3].

How is Nemolizumab Administered?

Nemolizumab is given as a subcutaneous injection, which means it’s injected just under the skin. In clinical trials, it’s typically administered every 4 weeks. The dosage can vary depending on the condition being treated and the patient’s body weight. For example:

  • For atopic dermatitis, doses of 30 mg or 60 mg are being studied[2]
  • For prurigo nodularis, patients weighing less than 90 kg receive 30 mg, while those weighing 90 kg or more receive 60 mg[3]

How Effective is Nemolizumab?

Clinical trials have shown promising results for nemolizumab in treating various skin conditions:

  • Atopic Dermatitis: Studies have shown that nemolizumab can significantly reduce itching and improve skin appearance in patients with moderate-to-severe atopic dermatitis. Many patients experienced a reduction in itching within the first few weeks of treatment[2][6].
  • Prurigo Nodularis: Trials have demonstrated that nemolizumab can reduce itching and improve the appearance of skin lesions in patients with prurigo nodularis[3].
  • Chronic Kidney Disease-Associated Pruritus: Early studies suggest that nemolizumab may be effective in reducing itching in patients undergoing hemodialysis who experience severe pruritus[4].

Safety and Side Effects

As with all medications, nemolizumab can cause side effects. In clinical trials, the most commonly reported side effects were:

  • Injection site reactions (redness, swelling, or pain at the injection site)
  • Upper respiratory tract infections
  • Headache

Researchers are closely monitoring the safety of nemolizumab, including any potential effects on the immune system. One study is specifically looking at how nemolizumab might affect the body’s response to certain vaccines[7].

Ongoing Research

Nemolizumab is still being studied in various clinical trials. These studies aim to:

  • Further evaluate the long-term safety and effectiveness of the drug[8]
  • Determine the optimal dosing regimens for different conditions
  • Assess its effectiveness in different age groups, including children and adolescents with atopic dermatitis[2]
  • Explore its potential in treating other conditions, such as systemic sclerosis[5]

It’s important to note that while the results so far are promising, nemolizumab is still an investigational drug. More research is needed before it can be approved for general use. Patients interested in nemolizumab should discuss with their healthcare provider whether participating in a clinical trial might be appropriate for their situation.

Aspect Details
Primary Conditions Studied Moderate-to-severe atopic dermatitis, prurigo nodularis, systemic sclerosis
Administration Method Subcutaneous injection, typically every 4 weeks
Key Efficacy Measures Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), Peak Pruritus Numeric Rating Scale (PP NRS)
Safety Monitoring Adverse events, injection site reactions, infections, immune system effects
Study Populations Adults and adolescents (12 years and older), some pediatric studies (2-11 years)
Trial Designs Randomized, double-blind, placebo-controlled studies; long-term safety and efficacy studies
Additional Outcomes Quality of life measures, sleep disturbance, pharmacokinetics, immunization responses

FAQ

  • What is nemolizumab and how does it work? Nemolizumab is an investigational drug that targets a specific pathway involved in itching and inflammation. It works by blocking a protein called interleukin-31, which is thought to play a key role in atopic dermatitis symptoms like itching and skin inflammation.
  • What skin conditions is nemolizumab being studied for? Nemolizumab is primarily being studied for moderate-to-severe atopic dermatitis. It is also being evaluated for other skin conditions like prurigo nodularis and systemic sclerosis in some trials.
  • How is nemolizumab administered in clinical trials? In most trials, nemolizumab is given as a subcutaneous (under the skin) injection, typically every 4 weeks. Some studies use different dosing regimens or compare different administration methods like auto-injectors versus syringes.
  • What are some of the main outcomes being measured in nemolizumab trials? Key outcomes include improvements in itch intensity, skin lesions, quality of life measures, and overall disease severity scores like the Eczema Area and Severity Index (EASI) and Investigator's Global Assessment (IGA).
  • Are there any safety concerns with nemolizumab from the clinical trials? While safety is still being evaluated, most trials are monitoring for adverse events, with special interest in injection site reactions, infections, and any potential effects on the immune system. Long-term safety studies are ongoing to gather more data.

Ongoing Clinical Trials on Nemolizumab

  • Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Estonia France +8

  • Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Denmark France Germany Hungary +5

  • Study on Nemolizumab for Children Aged 2-11 with Moderate-to-Severe Atopic Dermatitis Not Controlled by Topical Treatments

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary Poland Spain

Glossary

  • Atopic Dermatitis: A chronic inflammatory skin condition characterized by itchy, red, swollen, and cracked skin. It is the most common type of eczema.
  • Prurigo Nodularis: A skin condition characterized by hard, itchy lumps (nodules) that develop on the skin as a result of chronic scratching or picking.
  • Systemic Sclerosis: A rare autoimmune disease that causes hardening and tightening of the skin and connective tissues.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue between the skin and the muscle.
  • Eczema Area and Severity Index (EASI): A tool used to measure the extent and severity of atopic dermatitis, considering factors like redness, thickness, scratching, and the area of skin affected.
  • Investigator's Global Assessment (IGA): A scale used by healthcare professionals to evaluate the overall severity of a skin condition, typically ranging from 'clear' to 'severe'.
  • Peak Pruritus Numeric Rating Scale (PP NRS): A scale used by patients to rate the intensity of their worst itch over the past 24 hours, ranging from 0 (no itch) to 10 (worst itch imaginable).
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Placebo: An inactive substance or treatment used in clinical trials to compare the effects of a drug against a control group.
  • Anti-Drug Antibodies (ADA): Antibodies produced by the body's immune system in response to a therapeutic drug, which can potentially affect the drug's efficacy or safety.

References